In 2000 was created KIZOO, which is appeared as VC. The company was established in Europe in Germany. The main department of described VC is located in the Karlsruhe.
Besides them, we counted 2 critical employees of this fund in our database.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the KIZOO, startups are often financed by Runa Capital, Point Nine Capital, HW Capital. The meaningful sponsors for the fund in investment in the same round are Runa Capital, Point Nine Capital, Capnamic Ventures. In the next rounds fund is usually obtained by Runa Capital, Point Nine Capital, Capnamic Ventures.
This KIZOO works on 20 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. The fund is generally included in 2-6 deals every year. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 5 - 10 millions dollars. The increased amount of exits for fund were in 2018.
The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight AgeX Therapeutics, Lysoclear, Suitepad. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Cloud Computing, Software.
| Fund Name | Location |
| Aaban | - |
| Claris Lifesciences | Ahmedabad, Gujarat, India |
| CreditEase | Beijing, Beijing, China |
| DARPA | Arlington, United States, Virginia |
| Enigmo | Chiyoda, Japan |
| Forest Oil Corporation | Colorado, Denver, United States |
| Furukawa Ringyo | Japan, Tokyo |
| Harmony Labs | - |
| JDHC Asset Management | Beijing, China, Haidian |
| Jiaxing Huoyanhui Yihao Touzi Guanli Hehuo Qiye (Youxian Hehuo) | China, Jiaxing, Zhejiang |
| KCG Holdings | Jersey City, New Jersey, United States |
| LA Angels LLC | - |
| lenuo Touzi | China, Ningbo, Zhejiang |
| MBU Capital | England, London, United Kingdom |
| Negos Holding | - |
| Transform VC | California, San Francisco, United States |
| Yiqin Capital Management | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cellvie | $5M | 06 Feb 2023 | Houston, Texas, United States | ||
Mogling Bio | 26 Oct 2022 | Wilmington, Delaware, United States | |||
Elastrin Therapeutics | $10M | 07 Apr 2022 | South Carolina, United States | ||
Revel Pharmaceuticals | $8M | 17 Mar 2022 | San Francisco, California, United States | ||
Underdog Pharmaceuticals | $10M | 23 Sep 2021 | Mountain View, California, United States | ||
Elastrin Therapeutics | $2M | 04 Mar 2021 | South Carolina, United States | ||
Cellvie | $5M | 25 Jan 2021 | Houston, Texas, United States | ||
Elevian | $15M | 24 Nov 2020 | Boston, Massachusetts, United States | ||
Staffbase | $12M | 01 Oct 2020 | Chemnitz, Saxony, Germany |
– Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
– It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
– Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
– The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cellvie | $5M | 06 Feb 2023 | Houston, Texas, United States | ||
Mogling Bio | 26 Oct 2022 | Wilmington, Delaware, United States | |||
Elastrin Therapeutics | $10M | 07 Apr 2022 | South Carolina, United States | ||
Revel Pharmaceuticals | $8M | 17 Mar 2022 | San Francisco, California, United States | ||
Underdog Pharmaceuticals | $10M | 23 Sep 2021 | Mountain View, California, United States | ||
Elastrin Therapeutics | $2M | 04 Mar 2021 | South Carolina, United States | ||
Cellvie | $5M | 25 Jan 2021 | Houston, Texas, United States | ||
Elevian | $15M | 24 Nov 2020 | Boston, Massachusetts, United States | ||
Staffbase | $12M | 01 Oct 2020 | Chemnitz, Saxony, Germany |
